To: President Donald Trump, The United States House of Representatives, and The United States Senate
Pay the People
Public funding of research and research done at public institutions should have a return to the Public. Often a great deal of public money goes to research into new medicine, both the basic and advanced stages. These nearly finished drugs are then bought from the Universities and big Drug companies take the credit and the profit. It's time to see the Public's contribution returned.
A percentage of the basic development costs of all drugs should be returned to the investors. If the basic research or more advanced research was done at a university or other public institution then a percentage of the profits from that medication while under patent should be returned to further other research, help reduce the cost of the medication or in some way benefit the People.
10 or 20 years of basic research at public expense should not be sold for a one time payment to a private entity. Get our share of the profit, our return on investment from the Big Drug Companies.
A percentage of the basic development costs of all drugs should be returned to the investors. If the basic research or more advanced research was done at a university or other public institution then a percentage of the profits from that medication while under patent should be returned to further other research, help reduce the cost of the medication or in some way benefit the People.
10 or 20 years of basic research at public expense should not be sold for a one time payment to a private entity. Get our share of the profit, our return on investment from the Big Drug Companies.
Why is this important?
Most medicine on the market is found though basic research and then developed to a certain level with part or all of public, tax payer funding in colleges and universities. Currently, when the final product is released no percent of the profit comes back to the people of the US that funded the research. Let's get a percent of the profit returned to the People.